Francesca Satolli
Parma, 43126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 114 publications
Efficacy of Bimekizumab on Palmoplantar Psoriasis: A 16-Week Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis).
Journal: Journal of clinical medicine
Published: April 17, 2026
Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 11, 2026
Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.
Journal: Journal of cutaneous medicine and surgery
Published: March 17, 2026
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study.
Journal: The Journal of dermatological treatment
Published: February 06, 2026
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).
Journal: Dermatology and therapy
Published: December 01, 2025
Effectiveness of Bimekizumab in Multi-Failure Psoriatic Patients: A Retrospective, Real-World Multicenter Study.
Journal: Journal of personalized medicine
Published: November 26, 2025
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study.
Journal: Dermatology and therapy
Published: November 25, 2025
Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis).
Journal: Acta dermato-venereologica
Published: November 16, 2025
Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.
Journal: American journal of clinical dermatology
Published: November 05, 2025
Erythrodermic Psoriasis: Excellent Management Avoiding Hospitalization.
Journal: Acta dermatovenerologica Croatica : ADC
Published: July 14, 2025
Last Updated: 09/26/2026